Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Pyrotinib by Jiangsu Hengrui Medicine for Breast Cancer: Likelihood of Approval
Pyrotinib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Breast Cancer. According to GlobalData,...
Data Insights
Pyrotinib by Jiangsu Hengrui Medicine for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Pyrotinib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According...